Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers have reported the results of the first randomised clinical trial to test a novel strategy. The approach involves waking up and then killing the ‘sleeping’ HIV that is hiding in the body using an experimental approach known as ‘kick and kill’.

Led by Imperial College London, the University of OxfordMRC Clinical Trials Unit at UCL, and the University of Cambridge, the RIVER study aimed to improve on current care by eradicating HIV from the body, which would represent a major step forward in the search for a cure

Read the full article

Similar stories

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland

HIV vaccine trial starts at Oxford

NDM's Jenner Institute today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

RECOVERY Trial identifies another effective COVID-19 treatment

The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found that a monoclonal antibody combination developed by US company Regeneron reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response.

NDM Researchers recognised in Queen’s Birthday Honours

The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.